In this article, we will discuss the 10 Best Nancy Pelosi Stocks to Buy in 2026.
Nancy Pelosi is one of the most closely tracked members of Congress owing to her impressive record on Wall Street. Despite announcing plans to retire from Congress, her term runs until January 2027, giving investors time to access her investment portfolio.
Over the past decade, Pelosi’s portfolio has generated an estimated cumulative return of 838%, beating the S&P 500’s 256%. In 2024, her portfolio rose 70.9%, dwarfing the S&P 500’s 24.9% gain. In 2025, Pelosi’s portfolio still topped the S&P 500’s 14% gain, gaining 18%.
Before assuming public office in 1987, Pelosi and her husband had between $610,000 and $785,000 in their portfolio, worth over $133.7 million today. That means Pelosi has generated an average return of 16,930% over the past 37 years, dwarfing the Dow Jones Industrial Average’s 2,300% return over the same period. Amid the stellar gains, Pelosi’s net worth has skyrocketed to over $278 million.
Tracking members of Congress’s trading activity has grown in popularity in recent years, as it is believed they tend to beat the market due to their access to crucial insider information. Consequently, Pelosi’s portfolio is yet again in the spotlight after revealing more than $10 million in cumulative stock transactions.
The former House speaker has provided insights on some sectors to keep a close watch on, even as the overall equity market flirts with record highs amid premium valuations. A recent financial disclosure of January 23, 2026, indicates a series of high-value transactions executed by her spouse, Paul Pelosi. The moves totaling $69 million reflect strategic repositioning in tech giants and energy plays.
Our Methodology
To identify the 10 Best Nancy Pelosi Stocks to Buy Right Now, we used Capitol Trades, a platform that tracks the stock trading activity of politicians in the United States. The following stocks were selected from recent public investment disclosures by Pelosi and her family. Finally, we ranked the stocks in ascending order by the number of hedge funds holding stakes in them in Q3 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research shows we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
Best Nancy Pelosi Stocks to Buy in 2026
10. AllianceBernstein Holding L.P. (NYSE:AB)
Number of Hedge Fund Holders: 6
AllianceBernstein Holding LP (NYSE:AB) is one of the best Nancy Pelosi stocks to buy in 2026. The stock has been on an impressive run, rallying 10% year to date, outperforming the S&P 500, which is up by over 1.7% the same period. With the rally, the stock has powered to 52-week highs backed by an impressive 8.21% dividend yield.
On January 28, AllianceBernstein Holding LP (NYSE:AB) announced that its NAV Lending team within AB Private Credit Investors has rebranded as AB-PCI Fund & Manager Finance (FMF), highlighting its expanded ability to provide non-dilutive capital at both the fund and management company level. The rebrand underscores AB-PCI’s growing commitment to the private equity ecosystem, leveraging its experienced leadership team and market-leading private credit platform to deliver flexible, partnership-oriented financing solutions across private markets.
On January 27, Kore.ai announced a strategic growth investment led by AllianceBernstein Private Credit Investors to support the company’s next phase of growth, including expanded go-to-market efforts and accelerated innovation across its agentic AI platform, building on strong enterprise momentum and deepened partnerships with Microsoft and AWS.
Earlier on January 12, the company confirmed its assets under management increased to $867 billion in December from $865 billion in November. The $2 billion increase was driven by market appreciation, as total net flows remained negative in the month. Private Wealth inflows and institutional inflows were offset by Retail outflows. For the quarter ended December, net outflows totaled $5 billion.
Meanwhile, on January 15, Barclays reiterated an Equal Weight on the stock but cut the price target to $39 from $42. The price target cut is in response to changes in the company’s asset manager models that now fully reflect quarterly fund flows and assets under management
AllianceBernstein Holding L.P. (NYSE:AB) is a leading global investment management and research firm that provides diversified investment services to institutional investors, individuals, and private wealth clients. As of mid-2025, the firm managed approximately $829 billion in assets.
9. Tempus AI, Inc. (NASDAQ:TEM)
Number of Hedge Fund Holders: 32
Tempus AI, Inc. (NASDAQ:TEM) is one of the best Nancy Pelosi Stocks to buy in 2026. On January 27, Tempus AI, Inc. (NASDAQ:TEM) confirmed that its Immune Profile Score Test accurately predicts patient outcomes for immune checkpoint inhibitor therapy, compared with conventional biomarkers. Consequently, it continues to demonstrate superior predictive accuracy, with a hazard ratio of 0.45.
On January 21, Tempus AI introduced Paige Predict, an AI-powered digital pathology tool designed to analyze H&E whole slide images and predict 123 biomarkers across 16 cancer types, helping clinicians decide which confirmatory tests to run when tissue samples are limited. Built following Tempus’s 2025 acquisition of Paige, the tool is based on a foundation model trained on data from more than 200,000 patients and validated across multiple datasets. Despite operating at a loss, Tempus reported a 61.7% gross margin and says Paige Predict supports its broader goal of advancing precision medicine by embedding actionable insights directly into clinical reports.
Earlier on January 11, Tempus AI, Inc. announced a record Total Contract Value exceeding $1.1 billion at the end of 2025.
The $1.1 billion milestone came on the company’s signing of data agreements with over 70 customers spanning large and midsize companies. Some of the big customers the company inked deals with include AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, and Novartis. In addition, the company achieved a net revenue retention of 126%, affirming the strengthening of relationships with existing customers.
“2025 was a record year for our Data and applications business – both from a revenue and TCV perspective,” said Jim Rogers, Chief Financial Officer at Tempus. “Our engagement with life sciences companies has never been stronger, and our data business has never been better positioned, giving us tremendous visibility to continued growth in 2026 and beyond.”
Tempus AI, Inc. (NASDAQ:TEM) is a technology company that applies artificial intelligence (AI) to precision medicine, primarily focusing on collecting and analyzing clinical and molecular data to help physicians personalize care.
